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Background: Piwi-interacting RNAs (piRNAs) are small RNAs of 27–30 nucleotides mapping to transposons or
clustering in repeat genomic regions. Preliminary studies suggest an important role in cancerogenesis. This
study is the first one investigating their prognostic impact in clear cell renal cell cancer (ccRCC) patients.
Methods: Three piRNAs (piR-30924, piR-57125, and piR-38756) selected on the basis of initial piRNA microarray
analyses were determined using RT-qPCR in non-metastatic (n = 76) and metastatic (n = 30) ccRCC tissue at the
time of nephrectomy in comparison to normal renal tissue (n = 77) and tissue from distant ccRCC metastases
(n = 13). Primary clinical end points were recurrence-free and overall survival.
Results: piR-57125 showed lower expression in metastatic than in non-metastatic tumors, whereas the expression
of piR-30924 and piR-38756 increased in metastatic tumors. The higher expression of piR-30924 and piR-38756 as
well as the lower expression of piR-57125 in metastatic primary tumors were significantly associated with tumor
recurrence and overall survival. Multivariate Cox regression analyses revealed both piR-30924 and piR-57125 as
independent prognostic predictors. This impact was even more pronounced in non-metastatic patients.
Conclusions: This study demonstrates that the expression levels of these piRNAs in primary non-metastatic and
metastatic ccRCC tissue can serve as potential prognostic biomarkers in combination with clinicopathological factors.
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Renal cell cancer (RCC) comprises 2.4 % of all adult ma-
lignancies worldwide and is one of the ten most frequent
cancers with a continuously increasing incidence of
2.5 % expected, accompanied with one of the highest
cancer-specific mortality rates [1, 2]. Worldwide, RCC
accounted for 338 000 new cases and 144 000 deaths in
2012. Incidence rates of 6 per 100 000 in men and 3 per
100 000 in women and corresponding mortality rates of
2.5 and 1.2 per 100 000, respectively have estimated [1].
It is important from the clinical point of view to distin-
guish between different histological RCC subtypes [3].
Clear cell RCC (ccRCC) is the most common histo-
logical subtype accounting for approximately 80–90 % of* Correspondence: klaus.jung@charite.de
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creativecommons.org/publicdomain/zero/1.0/all RCCs, followed by papillary RCC at 6–15 % and chro-
mophobe RCC at 2–5 %. The majority of participants at
the International Society of Urological Pathology consen-
sus conference 2012 agreed that the main morphotypes of
RCC are significant prognosticators [4]. In text books and
also guidelines, a significantly worse prognosis is outlined
for patients with ccRCC after nephrectomy compared
with patients suffering from papillary or chromophobe
RCC [3, 5]. However, the study results are not at all con-
sistent [6, 7]. It should be considered that patients with
papillary RCC type 1 have a more favorable outcome than
those with type 2 [8]. This feature correspond to the
observation that two subgroups of papillary RCC can be
distinguished, one with a better and another with a worse
prognosis in comparison to ccRCC [7]. After a curatively
intended nephrectomy, approximately 30 % of RCC
patients develop metastases with an average survival time
of about 24 months [9]. Thus, there is an urgent need for
a better prediction of high risk RCC patients to applyticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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ever, current prognostic models based on conventional
clinicopathological and imaging data have limited accur-
acy and need further improvements [11]. New molecular
markers might be helpful for improving not only diagno-
sis, but also risk assessment and prediction of the thera-
peutic response in RCC patients [10–12].
In this respect, small non-coding RNAs like microRNAs
(miRNAs) have attracted special attention because of their
role as key regulators of gene expression [13]. Another
novel class of small RNAs, termed Piwi-interacting RNAs
(piRNAs) has essential functions in stem cell division,
apoptosis, and epigenetic control of transposons and telo-
mers, but also in translational regulation [14]. These
RNAs were first discovered in the testis [15, 16]. In con-
trast to miRNAs with approximately 20–24 nucleotides,
the length of piRNAs is about 26–33 nucleotides.
Recently, 32 194 and 32 826 piRNA sequences have been
listed in the two most comprehensive piRNA data bases
(http://pirnabank.ibab.ac.in/; http://www.regulatoryrna.org/
database/piRNA/) [17, 18]. Seventy to eighty percent of all
these piRNA sequences have been found on unique gen-
omic loci with the remaining 20–30 % on multiple gen-
omic loci. Early studies on different tumor types like
gastric, colon, lung, and breast cancer showed that dysreg-
ulated piRNAs can be involved, just like miRNAs, in
cancerogenesis [19–25]. However, in ccRCCs as the most
frequent RCC, no studies have yet been conducted in view
of the profile of piRNAs and their potential use as diagnos-
tic and prognostic biomarkers in this cancer.
Therefore, the aims of this study were (a) to characterize
the piRNA expression profile in ccRCC using an explora-
tory microarray technology, (b) to investigate three piR-
NAs selected on the basis of microarray results as
differentially expressed examples and to evaluate the ex-
pression profiles in non-metastatic and metastatic primary
ccRRCC in comparison to normal renal parenchyma
distant from the tumor [26] or tissue from distant ccRCC
metastases [27] using quantitative real-time reverse-
transcription polymerase chain reaction (RT-qPCR), (c) to
estimate the possible associations between expression pat-
terns and clinicopathological data, and (d) to characterize
their prognostic potential with regard to tumor recurrence
and overall survival.
Materials and methods
The study was approved by the institutional Ethics Com-
mittee (EA1/153/07; EA1/134/12) and was conducted in
compliance with the declaration of Helsinki. Reporting in
this study follows the REMARK criteria [28].Patients and tissue samples
The study included 106 patients undergoing radical
nephrectomy for non-metastatic or metastatic primaryccRCC between 2003 and 2010. In this study group,
there was radiological evidence of metastases in 30
patients at the time of surgery while 76 patients were
free of metastases. This was a retrospective study. The
number of patients was based on sample size calcula-
tions to reach a sufficient power of this study (α = 5 %,
β = 80 %) as explained in Additional file 1: Supporting
Information S1. Samples collected in the above men-
tioned period were then selected at random according to
the availability of cryo-preserved tissue. Tumor tissue
and normal renal parenchyma distant from the tumor, as
recently suggested as sampling approach for nephrectomy
samples [26, 29], were immediately sampled after nephrec-
tomy, either snap frozen in liquid nitrogen or immersed in
RNA Later solution (Qiagen, Hilden, Germany) and stored
at −80 °C as previously described [30, 31]. We defined a
necessary distance of >20 mm to the cancer tissue to be
absolutely asure of lowest possible alteration of the non-
neoplastic tissue through the tumor. That would also take
into account the theory of the field effect that cells in the
proximity to cancer could exhibit characteristics of the
cancer cells [32]. Thus, missing normal tissue samples due
to large tumor sizes of some patients omitting normal
tissue sampling or other procedure associated reasons as
recommended by Srigley et al. [29] resulted in 77 normal
and 106 tumor samples. Additionally, 13 bone metastatic
ccRCC specimens were sampled. No patients had received
systemic therapy prior to tissue collection. The tumors
were classified according to the 2002 TNM classification
and the Fuhrman grading system by an experienced path-
ologist (EK) [33, 34].
RNA extraction
Isolation of total RNA, its quantification and quality char-
acteristics were performed as previously reported [30, 31].
Frozen histologic sections, stained with hematoxylin/
eosin, were prepared from the stored tissue samples for
the extraction of total RNA. Only samples with at least
80 % tumor cells and without significant areas of necrosis
or fibrosis were used. About 30–60 mg of tissue pieces
were disrupted in QIAzol Lysis Reagent (Qiagen) with
5 mm stainless steel beads using the TissueLyser System
(Qiagen). Homogenates were used for the isolation of total
RNA using the miRNeasy Mini Kit (Qiagen) including an
optional on-column DNA digestion step according to the
producer’s instructions. Total RNA was eluted from the
spin column after different washing steps with 30 μl
RNase-free water. In this way, the isolated total RNA also
included all RNAs <200 nt. RNA samples were spectro-
photometrically quantified and characterized by the ratio
of the absorbance measured at 260 nm to that at 280 nm
(NanoDrop Technologies, Wilmington, DE, USA) and by
the RNA integrity number using a Bioanalyzer 2100 (Agi-
lent Technologies, Santa Clara, CA, USA) with a RNA
Busch et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:61 Page 3 of 116000 Nano Lab Chip, as previously described [30]. The
median ratio of 260 nm to 280 nm and the median RNA
integrity number of all the isolated RNA samples were
2.03 (95 % CI, 2.03–2.04) and 7.65 (95 % CI, 7.40–7.80),
respectively. The median RNA yield from one mg wet
weight of tissue was 716 ng (95 % CI, 664–777 ng).
Microarray analysis and selection criteria of piRNA for
further analysis
Three RNA pools containing equal amounts of total
RNA from five different non-metastatic ccRCC tissue
samples and five different normal tissue samples as
defined above were examined as a custom order by
ArrayStar Inc., Rockville, MD, USA. For that purpose,
one microgram of each pooled sample was 3′-end-fluo-
rescently labelled with Cy3. The labelled samples were
hybridized on the ArrayStar HG19 piRNA microarray
that was designed for profiling of about 23 000 human
piRNAs. The array images and subsequent data were an-
alyzed using software from Agilent Technologies, Santa
Clara, CA, USA (Agilent Feature Extraction software,
version 10.7.3.1; GeneSpring GX v11.5.1 software pack-
age). Quantile normalization of data was applied. Differ-
entially expressed piRNAs were identified using a
Volcano plot (Additional file 1: Supporting Information
S2 and Figure S1) and the individual data are listed in a
separate Excel file (Additional file 2: Supporting Infor-
mation Excel file). We defined as selection criteria for
the further quantitative validation of piRNAs using
RT-qPCR a differential expression of fold change >3
with p-values <0.005 and a high intensity (raw intensity
in the chip analysis >700). Thus, the upregulated piR-
38756 and the downregulated piR-57125 were selected
for further analysis. piR-30924 was additionally included
in this program (Additional file 1: Supporting Informa-
tion Figure S1) since this piRNA was shown in one of
the first clinically oriented piRNA studies in cancer to
be a useful tumor marker [20]. In the following, we used
the piRNA names of the data base of the National
Center for Biotechnology Information, Rockville, USA
(http://www.ncbi.nlm.nih.gov/) instead of the long NCBI
accession numbers or the accession numbers of the
other mentioned data bases [17, 18].
Quantitative RT-PCR
piR-30924, piR-38756, and the two miRNAs miR-28 and
miR-106a as reference genes were determined according
to the principle of the TaqMan RT-qPCR assay (Applied
Biosystems, Foster City, CA), as previously described
[30, 35, 36], while piR-57125 was determined using the
miScript PCR system (Qiagen, Hilden, Germany). Cus-
tomized assays were used for piRNA measurements. All
methodical details including the MIQE guideline check-
list [37], the PCR product controls, and precision controldata were compiled in the Additional file 1: Supporting
Information S3 including the Tables S2-S5 and Figure
S2. qPCR measurements were performed on the Light-
Cycler 480 (Roche, Mannheim, Germany).
Data analysis and statistics
RT-qPCR data were analyzed using the software qBase-
PLUS, version 2.6 (Biogazelle, Zwijnaarde, Belgium). Stat-
istical analyses were performed with SPSS 21 (SPSS Inc.,
Chicago, IL) using bootstrapping calculations, GraphPad
Prism 6.05 (GraphPad Software, La Jolla, CA), and Med-
Calc 14.8.1 (MedCalc Software, Ostend, Belgium). The
statistical tests (non-parametric: Mann–Whitney U-test,
Kruskal-Wallis test, Spearman rank correlation; paramet-
ric: ANOVA, Student’s t-tests with log-transformed data)
are mentioned in the corresponding places. Receiver oper-
ator characteristics (ROCs) with areas under the curve
(AUCs) and binary logistic regression served to identify
the discriminating capacity of piRNAs. The Kaplan-Meier
approach and Cox proportional hazard regression analysis
were used for disease progression analyses (overall sur-
vival and recurrence-free survival). The C-index was cal-
culated as a global measure for validating the predictive
reliability of survival models [38]. P < 0.05 (two-sided) was
considered statistically significant. GraphPad Statmate 2.0
(GraphPad Software) and MedCalc were used for sample
size determinations (α = 5 %, β = 80 %) as explained in
detail in Additional file 1: Supporting Information S1.
Results
Patient characteristics
The clinicopathological characteristics of the study co-
horts are compiled in Table 1. Thirteen metastatic ccRCC
specimens from bone metastases (12 male, one female;
median age: 69 years; range: 40–89) were additionally in-
vestigated to compare the expression characteristics of
piRNAs.
Differential expression of piRNAs and their relation to
clinicopathological data
235 upregulated and 369 downregulated piRNAs of 23 677
piRNAs on the microarray (>2 fold change, p < 0.05; details
in Additional file 1: Supporting Information S2) were
found in malignant in comparison to non-malignant tissue.
According to the above mentioned selection criteria for
further RT-qPCR analyses of piRNAs and to obtain deeper
insight into their differential expression in ccRCC, we se-
lected piR-38756, piR-57125, and piR-30924 measurements
in individual tissue samples of the study groups.
In Fig. 1, the RT-qPCR expression data of these three
piRNAs in normal tissue, non-metastatic and metastatic
primary tumor samples as well as in bone metastatic
ccRCC specimens are presented. miR-28 and miR-106a
were used as normalizers described in Additional file 1:
Table 1 Cohort characteristics, N = 106
Characteristics Primary ccRCC,
non-metastatica N = 76
Primary ccRCC,




65 (37–87) 61 (43–76) 0.153
Sex, n (%)
Male 58 (76) 21 (70) 0.621
Female 18 (24) 9 (30)
Pathological stage, n (%)
pT1 48 (63) 5 (17) <0.0001
pT2 2 (3) 1 (3)
pT3 25 (33) 21 (70)
pT4 1 (1) 3 (10)
Fuhrman grade, n (%)
G1 11 (14) 0 (0) <0.0001
G2 60 (79) 11 (37)
G3 3 (4) 16 (53)
G4 2 (3) 3 (10)
Surgical margins, n (%)
R0 71 (93) 21 (70) 0.003




48 (20–180) 85 (35–170) <0.0001
Patients
followed,c n (%)






12 (16) 25 (83)
Follow-up, median month (range)
Overall 65.7 (1.0–121) 9.5 (1.2–65.2) <0.0001
No recurrence 69.9 (5.3–121)
Recurrence 30.4 (1.0–116)
Abbreviations: ccRCC clear cell renal cell carcinoma, G histopathological grading
according to Fuhrman, pT pathological tumor classification, R surgical
margin classification
aImaging techniques was used to provide evidence of presence/non-presence
of metastases before surgery
bp value from Fisher’s exact test or Chi-square test for trend and
Mann–Whitney U-test
cIn four cases, only the survival but not the recurrence situation could
be assessed
Fig. 1 Expression of piRNAs in tissue samples from patients suffering
from clear cell renal cell carcinoma. Measurements of (a) piR-30924,
(b) piR-57125, and (c) piR-38756 were performed in normal renal
parenchyma distant from tumor (N, n = 77), in tissue from non-
metastatic (RCC-M0, n = 76) and metastatic primary tumor (RCC-M1,
n = 30) of patients with clear cell renal cell carcinoma at the time of
nephrectomy as well as in bone metastatic tissue samples (Meta,
n = 13) from patients suffering from renal cell carcinoma metastases.
The miRNAs miR-28 and miR-106a were used as normalizers according
to previous results on suitable reference genes for miRNA expression in
renal cell carcinomas [30]. Boxes in the box-and whisker plots represent
the lower and upper quartiles with medians, whiskers illustrate the
whole range of the samples. Significant differences between the study
groups were estimated by the one-way ANOVA test with multiple
comparisons corrected according to Holm-Sidak. Significances of at least
p< 0.05 are indicated by the following symbols: a, compared to “N”; b,
compared “RCC-M0”; c, compared to “RCC-M1”, and d, compared
to “Meta”
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ence genes for the expression of miRNAs, and thus also
for slightly longer piRNAs, in renal cell carcinomas dem-
onstrated the better accuracy of this combination of two
miRNAs in comparison to the conventionally used
RNU6B or RNU48 [30]. The expression rates of the three
piRNAs were not associated with age or sex (rS = 0.006–
0.151, p = 0.151–0.938). All three piRNAs had reduced ex-
pression in non-metastatic primary tumors in comparison
to normal renal tissue. Additionally, piR-57125 was lower
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sue compared to non-metastatic primary tumors, while,
on the contrary, piR-30924 and piR-38756 were signifi-
cantly upregulated in metastatic primary tumors and in
bone metastases compared to non-metastatic primary tu-
mors. Depending on tumor stage and grade, significantly
higher expression rates were found in tumor samples of
pT3 + 4 and Fuhrman G3 + 4 compared to those of pT1 +
2 or G1 + 2 for piR-30924 (geometric means of normalized
expression of 1.03 vs. 0.544, p = 0.008 and 3.43 vs. 0.604,
p < 0.0001, respectively) and piR-38756 (0.936 vs. 0.513,
p = 0.024 and 3.23 vs. 0.562, p < 0.0001, respectively), but
not for piR-57125 (0.682 vs. 0.709, p = 0.365 and 0.678 vs.
0.912, p = 0.366, respectively) (Additional file 1: Support-
ing Information Figure S3). Tumor size was significantly
correlated only with piR-30924 (rS = 0.305, p = 0.007) but
not with piR-57125 (rS = 0.001, p = 0.989) and piR-38756
(rS = 0.088, p = 0.447). Statistically significant associations
were not found between the surgical margin and all the
piRNAs (p = 0.068–0.302).
The expression of piR-30924 correlated with piR-57125
and piR-38756 (rS = 0.320, p < 0.0001 and rS = 0.578, p <
0.0001), but no correlation existed between the expression
of piR-57125 and piR-38756 (rS = 0.103, p = 0.151).
piRNAs as marker for tissue discrimination
In Table 2, the ROC analyses of piRNAs as tissue discrimi-
nators are summarized. A better discrimination between
non-malignant and malignant tissue samples than be-
tween metastatic and non-metastatic samples was
achieved; the correct classification rates were about 80 %.
piRNAs as prognostic markers
The RT-qPCR expression data of the piRNAs as shown in
Fig. 1 and their association to tumor stage and grade can
indeed be considered as an indication that piRNAs could
be used as prognostic markers in ccRCC patients. There-
fore, we assessed their predictive capacity regarding recur-
rence and overall survival. The time from the date of
surgery to the last follow-up or to tumor recurrence and
the determination of death, respectively, were used to
calculate the clinical endpoints times of recurrence or
overall survival.
To provide an initial overview, Kaplan-Meier curves
were calculated to assess the association of piRNA
expression data, which were dichotomized using the
cutoffs obtained in the ROC analysis at the point of
maximal accuracy (Youden index), and clinical outcomes
(Figs. 2 and 3). The cutoff values are displayed at the re-
spective curves. The overall survival and the recurrence-
free interval significantly decreased with increasing pT
stage and histological grade, thus demonstrating the
representativeness of the study cohorts. The higher
expression of piR-30924 and piR-38756 as well as thelower expression of piR-57125 in metastatic tumors and
bone metastases compared to the non-metastatic primary
tumors was significantly associated with the two clinical
endpoints. Subsequently, the prognostic performance of
the individual piRNAs was assessed together with the rele-
vant clinicopathological variables both in univariate and
fully and stepwise reduced multivariate Cox regression
analyses (Table 3). In univariate analyses, the hazard ratios
of piRNAs reflected the results of the Kaplan-Meier
curves. For the combined tumor group, including meta-
static and non-metastatic patients, the criterion “metasta-
sis” was the decisive factor for overall survival (Table 3).
However, the backward elimination approach of the multi-
variate Cox regression with all clinicopathological factors
and piRNAs showed that, in addition to the criterion “me-
tastasis”, both piR-30924 and piR-57125 remained in the
model as significant variables. On the other hand, the
prognostic significance of piR-38756 was especially indica-
tive in the non-metastatic patients as this piRNA alone
remained in the model as essential predictive variable to-
gether with the variable “Fuhrman grade”.
Internal validation of the results was performed by boot-
strapping and the calculation of the C-index [38]. The C-
indexes of the survival models showed both the global
prognostic ability of the three piRNAs and their additional
benefit if they were included into survival models based
only on clinicopathological variables (Table 3).
Discussion
Within the current study, we performed a genome-wide
expression analysis of piRNA by microarray to screen
for piRNAs differentially expressed in ccRCC and to val-
idate their potential clinical significance as biomarkers.
RT-qPCR analyses on three selected piRNAs showed for
the first time differentially expressed piRNAs in ccRCC
as well as a strong relationship between piRNA expres-
sion data and the clinical endpoints of recurrence-free
and overall survival. This study design as a hypothesis-
generating approach through discovery-driven global re-
search was recently suggested as one of the essential
steps for translational research in medicine to comply
with the realistic conditions in clinical settings [39].
We found that 1.56 % (n = 369) of the total 23 677 piR-
NAs examined were downregulated by least two-fold in
ccRCC while only 0.99 % (n = 235) were accordingly up-
regulated. This significantly higher percentage (p < 0.0001)
of downregulated piRNAs corresponded to a higher num-
ber of decreased miRNAs as another type of small RNAs
in ccRCC samples [35]. This result of differentially
expressed piRNAs prompted us to analyze three selected
piRNAs (piR-30924, piR-57125, and piR-38756) in more
detail. Although piR-38756 was overexpressed in micro-
array analysis, its downregulation was demonstrated by
RT-qPCR and verified by specific electrophoretic PCR
Table 2 Receiver-characteristic curve analyses of piRNAs to discriminate between non-malignant vs. malignant tissue and non-
metastatic vs. metastatic primary tumor tissue
piRNA AUC (95 % CI) P value different to AUC = 0.5 Differentiating ability at the Youden indexa Overall correct classification (%)
Sensitivity (95 % CI) Specificity (95 % CI)
Non-malignant/malignant tissue
piR-30924 0.61 (0.53–0.70) 0.008 75 (65–83) 47 (35–59) 57.3
piR-57125 0.87 (0.81–0.92) <0.0001 90 (82–95) 79 (69–88) 83.6
piR-38756 0.71 (0.64–0.78) <0.0001 43 (33–52) 95 (87–99) 58.5
All piRNAs combinedb 0.91 (0.86–0.95) <0.0001 91 (83–95) 86 (76–93) 85.8
Non-metastatic/metastatic
piR-30924 0.63 (0.54–0.73) 0.028 30 (15–49) 93 (85–98) 71.7
piR-57125 0.68 (0.58–0.77) 0.004 40 (23–59) 92 (84–97) 71.7
piR-38756 0.64 (0.54–0.73) 0.013 77 (58–90) 61 (49–72) 71.7
All piRNAs combinedb 0.76 (0.67–0.84) <0.0001 73 (54–88) 74 (62–83) 75.5
piR-30924 + piR-57125c 0.76 (0.67–0.84) <0.0001 73 (54–88) 74 (62–83) 75.5
Abbreviations: AUC area under the receiver-operating curve, CI confidence interval
aThe Youden index as a measure of overall diagnostic effectiveness is calculated by (sensitivity + specificity) - 1. When equal weight is given to sensitivity and
specificity of a test, the cutoff at the maximum value of this index, which graphically corresponds to the maximum vertical distance between the ROC curve and
the diagonal line, is referred to as optimal criterion
bCalculated by full binary logistic regression
cCalculated by stepwise binary logistic regression with all three miRNAs (backward likelihood elimination; entry p = 0.05, removal p = 0.10). In case of the
differentiation between non-malignant and malignant tissue, the backward elimination did not result in a reduced model
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tion Figure S2). This fact underscores again that specific
RT-qPCR measurements remain indispensable for the val-
idation of microarray analyses [40, 41]. Other studies
found approximately 6–10 % discordant microarray re-
sults compared to RT-PCR measurements [40]. Moreover,
piR-30924, which we selected for comparative purposes as
a strongly upregulated piRNA in other cancers [20] was
expressed at a lower level in ccRCC than in normal tissue.
This discordant expression behavior between different tu-
mors conforms to a similar phenomenon observed in case
of miRNAs, probably as a consequence of their different
effects or resulting from specific signaling pathways in
various tumors [42].
Although all three selected piRNAs were downregulated
in non-metastatic ccRCCs in comparison to normal tissue,
they were characterized by different expression patterns in
the metastatic primary tumor and metastatic tissue from
bone metastases (Fig. 1). The uniformly reduced expres-
sion of piR-57125 in the sequence from the non-
malignant tissue over the primary non-metastatic and pri-
mary metastatic tumor to the distant metastases con-
trasted with the differently regulated expression of piR-
30924 and piR-38756 (Fig. 1). The expression of these two
piRNAs in samples from metastatic primary ccRCC and
distant ccRCC metastases was higher than in non-
metastatic ccRCC samples and reached again the level in
normal tissue distant from tumor. These differences of the
piRNAs were partly reflected by different expression
levels, depending on tumor stage and grade (Additional
file 1: Supporting Information Figure S3). Similarlycharacteristic behavior was also observed for miRNAs in
ccRCC [43].
In addition to these particularities, the evidence of the
investigated piRNAs as independent factors in multivari-
ate Cox regression analyses together with conventional
clinicopathological variables like tumor stage and/or
tumor grade demonstrates the potential of piRNAs as
orthogonal biomarkers [44]. This type of biomarker is
characterized by its uncorrelated differential expression
to established disease variables. In this case, piRNAs
provide an additional degree of information. Thus, the
specific feature of orthogonal markers offers the advan-
tage of discovering associations with new disease-related
pathways and downstream conditions that had not been
considered previously [44]. For predicting overall survival
both in non-metastatic and metastatic ccRCC patients
after nephrectomy, all three piRNAs were highly signifi-
cant indicators in univariate analyses (Table 3). More im-
portantly, both piR-30924 and piR-57125 remained
independent factors, together with the decisive variable
metastasis, in the Cox regression backward model for
these patients (Table 3). piR-38756 alone was an inde-
pendent factor together with tumor grade for predicting
recurrence and survival in non-metastatic patients
(Table 3). Thus, these data show that piRNAs might be
considered as potential new molecular markers that are
capable of improving risk stratification and prediction of
the therapeutic response in RCC patients. Recent prog-
nostic models, generally based only on clinicopathological
and imaging data, are of limited accuracy [11]. This view
and the potential improvement of these models using
Fig. 2 Kaplan-Meier analyses of overall survivals after surgical removal of non-metastatic and metastatic clear cell renal cell carcinoma. piRNAs
were dichotomized using their values (given in normalized units) obtained in the ROC analysis at the point of maximal accuracy to discriminate
between dead and alive. The curves from 76 non-metastatic and 30 metastatic patients listed in Table 1 are presented according to (a) pathological
stage, (b) grading, and expression of (c) piR-30924, (d) piR-57125, (e) piR-38756, and (f) combination of all three piRNAs. The log-rank test was used to
confirm significant differences between the survival probabilities
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study by the higher C-indexes of the Cox-regression
models if piRNAs were used in combination with standard
clinicopathological factors in comparison to models with
only clinicopathological variables (Table 3).
Expression studies of piRNAs with a focus on their diag-
nostic and prognostic validity and their functional role
have been examined in only a few other cancers [19–21,
23, 25]. As already mentioned, piR-30924 was found to be
upregulated in gastric cancer [20]. Transfection of an in-
hibitor of this piRNA into gastric cancer cells reduced cellproliferation by arresting cells in the G2/M phase. An
oncogenic role of this piRNA was assumed. In bladder
cancer, 106 up- and 91 down-regulated piRNAs were de-
scribed when similar differential expression criterion of a
>2-fold change was applied, as in our study [25]. The au-
thors used the same piRNA microarray and found piR-
60152 as the most profoundly downregulated piRNA.
Over-expression of this piRNA in bladder cancer cell lines
reduced cell proliferation and promoted apoptosis.
TNFSF4 was identified as a target gene of this piRNA.
piRNA-mediated effects were also characterized for other
Fig. 3 Kaplan-Meier analyses of recurrence-free survivals after surgical removal of non-metastatic clear cell renal cell carcinoma. piRNAs were
dichotomized using their values (given in normalized units) obtained in the ROC analysis at the point of maximal accuracy to discriminate
between recurrence and recurrence free. The curves include data from 72 of the 76 non-metastatic patients listed in Table 1 with available
follow-up data and are presented according to (a) pathological stage, (b) Fuhrman grading, and expression of (c) piR-30924, (d) piR-57125,
(e) piR-38756, and (f) combination of all three piRNAs. The log-rank test was used to confirm significant differences between the recurrence-free
intervals
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of the key challenges in our understanding of the function
of this class of small non-coding RNAs. Such findings
could lead to novel therapeutic implications of piRNAs. In
the case of the three studied piRNAs, piR-30924 is located
on chromosome 2 and 5 and piR-57125 on chromosome
5 whereas the sequence of piR-38756 has been found at
approximately 300 multiple loci. However, the recently re-
ported comprehensive molecular characterization of
ccRCC did not mention any relationships between typicalRCC hot spots and piRNAs [46]. In addition, sophisticated
search machines for target predictions of human piRNAs
like for miRNAs are planned but are currently not avail-
able [18, 47].
Nevertheless, with regard to the currently missing func-
tional data, it cannot be distinguished as to whether all
these different changes are part of the cause of cancero-
genesis and its progression or rather the consequence of
other processes taking place in cancer development. Re-
cently, the first manually curated piRNA data base (http://
Table 3 Cox proportional hazard regression analyses of clinicopathological factors and piRNAs for predicting overall and recurrence-
free survival in ccRCC patients after nephrectomy and C-indexes of the models
Overall survival analysisa Recurrence-free survival analysisa
All ccRCC patients (N = 106) Non-metastatic ccRCC (N = 76) Non-metastatic ccRCC (N = 72)
Variableb HR (95 % CI) P value HR (95 % CI) P value HR (95 % CI) P value
Univariate analysis
Age (continuous) 0.98 (0.96–1.01) 0.300 0.99 (0.94–1.04) 0.771 1.01 (0.97–1.05) 0.709
Gender 0.97 (0.46–2.04) 0.929 2.95 (0.39–22.8) 0.297 5.35 (0.72–39.8) 0.103
pT stage (pT1-2/pT3-4) 4.44 (2.14–9.93) <0.0001 3.57 (1.13–11.3) 0.031 3.47 (1.37–8.78) 0.009
Grade (G1-2/G3-4) 7.75 (3.91–15.4) <0.0001 17.3 (3.67–81.3) 0.003 4.73 (2.27–9.84) <0.0001
Margin (R0/R1-2) 2.51 (1.44–4.38) 0.001 3.15 (0.82–12.2) 0.098 6.23 (2.66–14.6) <0.0001
Tumor size (continuous) 1.01 (1.01–1.02) <0.0001 1.01 (1.01–1.02) 0.020 1.01 (1.01–1.02) <0.0001
Metastasis 11.6 (5.60–24.2) <0.0001 - - - -
piR-30924 2.90 (1.36–4.94) 0.004 3.11 (1.01–3.50) 0.049 2.89 (1.04–8.08) 0.044
piR-57125 0.30 (0.15–0.59) 0.0006 0.0 0.964 2.08 (0.82–5.25) 0.123
piR-38756 3.96 (1.87–8.37) 0.0003 5.40 (1.47–19.9) 0.012 2.66 (1.06–6.67) 0.038
Multivariate analysisc
T stage 0.72 (0.24–2.15) 0.718 1.42 (0.30–6.81) 0.658 1.57 (0.38–6.52) 0.536
Grade 1.17 (0.43–3.18) 0.760 8.32 (0.52–33.4) 0.135 7.75 (1.11–54.4) 0.039
Margin 1.57 (0.67–3.69) 0.298 1.08 (0.19–6.14) 0.935 2.50 (0.77–8.15) 0.127
Tumor size 1.00 (0.99–1.02) 0.603 0.99 (0.97–1.02) 0.457 1.00 (0.99–1.02) 0.743
Metastasis 8.41 (3.10–22.8) <0.0001 - -
piR-30924 2.04 (1.02–4.51) 0.046 1.10 (0.24–5.03) 0.899 1.50 (0.41–5.43) 0.540
piR-57125 0.50 (0.21–1.18) 0.112 - -
piR-38756 1.93 (0.72–5.16) 0.190 5.42 (0.99–29.8) 0.052 3.15 (1.96–9.32) 0.038
C-Index with all variablesd 0.854 0.759 0.803
C-Index without piRNAs 0.835 0.589 0.753
Multivariate analysis, backward eliminatione
Metastasis 11.0 (4.82–25.3) <0.0001 - - - -
Grade - - 8.00 (1.20–53.4) 0.032 27.8 (6.60–113) <0.0001
piR-30924 2.27 (1.13–4.58) 0.022 - - - -
piR-57125 0.44 (0.21–0.93) 0.031 - - - -
piR-38756 - - 5.67 (1.14–28.1) 0.034 3.22 (1.16–8.94) 0.025
C-Index of the model 0.840 0.749 0.741
Abbreviations: ccRCC clear cell renal cell carcinoma, CI confidence interval, C-Index concordance index, G histopathological grading according to Fuhrman, HR
hazard ratio, pT pathological tumor classification, R surgical margin classification
aThis study group included the two cohorts of non-metastatic (n = 76) and metastatic (n = 30) patients listed in Table 1; for the analysis of recurrence-free survival,
data from four patients could not be obtained
bCalculations were performed with categorization criteria as indicated in brackets and p values were obtained by bootstrapping (2000 resamples). piRNAs were
dichotomized using their values obtained in ROC analyses at the point of maximal accuracy to discriminate between dead and alive as well as between
recurrence and recurrence-free situation. The thresholds corresponded to those used in the Kaplan-Meier analyses in Figs. 2 and 3
cThe multivariate analysis included all variables of the univariate analyses with p values <0.10
dC-indexes [38] were calculated using models either with all variables or only with clinicopathological data without piRNAs
eThe multivariate analysis with the backward elimination approach was made with p = 0.05 for entry and p = 0.10 for removal. The 95 % CI of the hazard ratios
and the p values of the final model were obtained after bootstrapping
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to provide information from more than 130 data sets with
regard to the functions of piRNAs in the epigenetic and
post-transcriptional regulation of transposons and genes
[18]. However, the hitherto scarce insight into the func-
tional role of piRNAs was shown by the quality score <10of most of the piRNAs in the data base “GeneCards”, in-
cluding those measured in this study [48]. In this data
base that covers the most comprehensive list of approxi-
mately 80 000 non-redundant non-coding RNAs includ-
ing the piRNA class, this low score value characterizes
missing functional data and reliable expression profiling
Busch et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:61 Page 10 of 11studies. All these facts highlight that our understanding of
piRNAs is still very limited. Thus, although research on
piRNAs is still very much in its infancy and their func-
tional role remains widely unknown [49], these few first
results suggest that piRNAs could gain a comparable im-
portance for cancer research in the future as miRNAs
achieved some years before [50].
Some limitations of this study, like its retrospective de-
sign, the limited number of cases, and the small number
of analyzed piRNAs as well as the single-center character
of our analysis need to be addressed. Another critical
point was the missing normal tissue samples from all
nephrectomy samples. We explained it in the section “Ma-
terials and methods”. Thus, statistical tests for matched
pairs samples could not be performed. In comparison to
matched paired samples that consider the intra-individual
variability, the variability in groups is generally higher and
results in lower statistical power when differences of
group data are statistically tested. On the other hand, sta-
tistically significant differences detected between groups,
as in our study, are consequently a more stringent proof
of excluding a possible type II error. Further arguments
for the validity of our study are that all measurements
were performed in a blinded manner. In addition, at least
10 % more patients were analyzed than the calculated
sample size and an internal validation by bootstrapping
was performed to avoid type I and II errors. Despite con-
sideration of all these reasonable points, our study results
need to be validated by larger multicenter, prospective
studies. In such a study including sufficient cases for sep-
arate training and test sets, more highly differentially
expressed piRNAs as potential predictive and prognostic
biomarkers should be examined.
In conclusion, the analysis of piRNAs in ccRCC samples
based on genome-wide microarray and RT-qPCR measure-
ments demonstrated their strong association with tumor
progression, suggesting in their validity as diagnostic and
especially prognostic biomarkers. In combination with
standard clinicopathological data, piR-30924, piR-57125,
and piR-38756 have the potential to improve prognostic in-
formation for ccRCC patients. The results of this study
make further prospective studies worthwhile as a high
number of differentially expressed piRNAs were found.Additional files
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